Payment overview · 2025
General Payments
$183.83
11 reported records · 6 companies
Healthcare provider profile · identity verified
Tom S Kirkwood, MD
Allopathic & Osteopathic Physicians|Family Medicine · BICKNELL, IN · NPI 1801894621
Verified facts
What the public records show
CMS Open Payments records show Tom S Kirkwood, MD received $183.83 in general payments during 2025 across 11 reported records.
Novo Nordisk Inc accounted for 38.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 241 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $71.15 | 38.7% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.30 | 25.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.25 | 11.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.92 | 9.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.43 | 7.8% | 1 | 2025 |
| Sonex Health, Inc. | Unresolved — no canonical attribution shown | $13.78 | 7.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $183.83 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $57.23 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $57.23 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $46.30 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.43 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.43 | 1 | 2025 |
Source payment records
|
|||||
| SX-ONE MICROKNIFE Normalized: sx one microknife |
Device | Sonex Health, Inc. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 241 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 142 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
159 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
142 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
241 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 890 | 167 |
| Atorvastatin Calcium | Atorvastatin Calcium | 834 | 157 |
| Levothyroxine Sodium | Levothyroxine Sodium | 564 | 95 |
| Omeprazole | Omeprazole | 555 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 521 | 94 |
| Losartan Potassium | Losartan Potassium | 479 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 464 | 88 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 390 | 78 |
| Metformin Hcl | Metformin Hcl | 364 | 69 |
| Citalopram Hbr | Citalopram Hydrobromide | 327 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 319 | 63 |
| Gabapentin | Gabapentin | 287 | 57 |
| Alprazolam | Alprazolam | 278 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 257 | 53 |
| Potassium Chloride | Potassium Chloride | 255 | 56 |
| Eliquis | Apixaban | 241 | 31 |
| Furosemide | Furosemide | 240 | 51 |
| Montelukast Sodium | Montelukast Sodium | 234 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 220 | 41 |
| Simvastatin | Simvastatin | 211 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 202 | 28 |
| Glimepiride | Glimepiride | 184 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 172 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 170 | 30 |
| Finasteride | Finasteride | 168 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 167 | 30 |
| Jardiance | Empagliflozin | 159 | 25 |
| Meloxicam | Meloxicam | 146 | 27 |
| Ozempic | Semaglutide | 142 | 19 |
| Ezetimibe | Ezetimibe | 141 | 20 |
| Celecoxib | Celecoxib | 139 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 138 | 20 |
| Allopurinol | Allopurinol | 134 | 26 |
| Famotidine | Famotidine | 133 | 37 |
| Carvedilol | Carvedilol | 125 | 25 |
| Methylprednisolone | Methylprednisolone | 122 | 99 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 118 | 21 |
| Sertraline Hcl | Sertraline Hcl | 112 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 103 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 102 | 34 |
| Warfarin Sodium | Warfarin Sodium | 93 | 11 |
| Azithromycin | Azithromycin | 92 | 58 |
| Tramadol Hcl | Tramadol Hcl | 82 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 80 | 16 |
| Clonidine Hcl | Clonidine Hcl | 78 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 72 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 69 | suppressed |
| Prednisone | Prednisone | 67 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 65 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 62 | 13 |
| Diazepam | Diazepam | 61 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 61 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 61 | 16 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 60 | 25 |
| Cephalexin | Cephalexin | 59 | 42 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 11 |
| Lorazepam | Lorazepam | 59 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | suppressed |
| Temazepam | Temazepam | 56 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 55 | 12 |
| Entresto | Sacubitril/Valsartan | 54 | suppressed |
| Synthroid | Levothyroxine Sodium | 54 | 15 |
| Gemfibrozil | Gemfibrozil | 51 | 11 |
| Spironolactone | Spironolactone | 51 | suppressed |
| Nifedipine Er | Nifedipine | 48 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 33 |
| Meclizine Hcl | Meclizine Hcl | 46 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 45 | suppressed |
| Sucralfate | Sucralfate | 45 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 44 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | suppressed |
| Estradiol | Estradiol | 43 | 17 |
| Terbinafine Hcl | Terbinafine Hcl | 43 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 42 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 14 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Amoxicillin | Amoxicillin | 41 | 36 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 19 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | suppressed |
| Baclofen | Baclofen | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Acyclovir | Acyclovir | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 16 |
| Atenolol | Atenolol | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 14 |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Cartia Xt | Diltiazem Hcl | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 18 |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 13 |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Roflumilast | Roflumilast | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Methadone Hcl | Methadone Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Perindopril Erbumine | Perindopril Erbumine | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | 11 |
| Silodosin | Silodosin | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $183.83 · 11 records | Novo Nordisk Inc | ELIQUIS, EVENITY, MOUNJARO, NURTEC ODT, Ozempic, PROLIA, Rybelsus, SX-ONE MICROKNIFE, TRELEGY ELLIPTA, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error